Quantum Biopharma has completed dosing in two toxicology studies requested by the U.S. Food and Drug Administration (FDA) that aim to support the launch of clinical studies of Lucid-MS, an experimental treatment for multiple sclerosis (MS) that’s designed to slow myelin loss. The 180-day toxicity and toxicokinetic studies were designed to evaluate any potential harmful […]
The post Myelin-targeting drug Lucid-MS inches closer to testing in patients appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com